Conference LibraryGated
ESO-T01 · feasibility signal · in vivo CAR-T generation in human
ESO-T01 phase 1(9 patients · r/r MM)的 feasibility 维度信号: - 9/9 patients 在体内成功生成 CAR-T 细胞(per Nature Medicine 2026 + Lancet 2025) - CAR-T levels similar to ex vivo delivery - extramedullary lesion elimination 在多名患者报告 - 3-4 month follow-up(尚短 · long-term outcome unknown) 这是 in vivo…
- Type
- evidence
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- in_vivo_car_t_feasibility
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "feasibility demonstration only · 3-4 month follow-up insufficient for long-term outcome claim · NOT validated late-stage clinical model"
- indication
- relapsed/refractory multiple myeloma
- patient_count
- 9
- trial_id
- IIT in China · per EsoBiotec 2024-12-11 PR
- efficacy_summary
- 9/9 in vivo CAR-T generation success · CAR-T levels similar to ex vivo · extramedullary lesion elimination signal · 3-4 month follow-up (insufficient for long-term claim) · feasibility demonstration o
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.